Table 3 Results of analysis of effectiveness and safety of low-dose DOAC (ld-DOAC) versus phenprocoumon

 Ld-DOAC

−24.0%

−0.6% [− 1.0%; − 0.2%]

− 172

.002*

1.29 [1.13; 1.48]

< .001*

 Ld-Apixaban

−42.1%

−1.1% [− 1.7%; − 0.6%]

−89

< .001*

1.42 [1.21; 1.65]

< .001*

 Ld-Dabigatran

−6.0%

−0.2% [− 1.2%; 0.9%]

− 636

0.842

1.04 [0.77; 1.39]

.810

 Ld-Edoxaban

−10.0%

−0.3% [− 1.3%; 0.7%]

− 373

0.651

1.25 [0.95; 1.65]

.112

 Ld-Rivaroxaban

−7.0%

−0.2% [− 0.7%; 0.4%]

− 589

0.575

1.20 [1.00; 1.44]

.053

 Ld-DOAC

−56.9%

−4.2% [− 4.9%; −3.5%]

−24

< .001*

1.52 [1.41; 1.63]

< .001*

 Ld-Apixaban

−59.0%

−5.7% [−6.6%; − 4.7%]

−18

< .001*

1.63 [1.50; 1.76]

< .001*

 Ld-Dabigatran

10.4%

0.8% [−0.9%; 2.6%]

119

0.361

1.12 [0.94; 1.34]

.193

 Ld-Edoxaban

−31.0%

− 3.0% [−4.8%; −1.1%]

−34

.002*

1.40 [1.22; 1.60]

< .001*

 Ld-Rivaroxaban

−34.5%

−2.8% [− 3.8%; −1.8%]

−36

< .001*

1.45 [1.32; 1.59]

< .001*

 Ld-DOAC

16.7%

0.6% [0.2%; 1.1%]

156

0.003

0.89 [0.79; 1.00]

.051

 Ld-Apixaban

27.2%

1.2% [0.6%; 1.8%]

83

< .001*

0.75 [0.65; 0.86]

< .001*

 Ld-Dabigatran

11.9%

0.4% [−0.8%; 1.5%]

273

0.563

0.86 [0.64; 1.14]

.298

 Ld-Edoxaban

8.7%

0.4% [−0.8%; 1.5%]

279

0.590

0.95 [0.75; 1.21]

.700

 Ld-Rivaroxaban

3.8%

0.2% [−0.5%; 0.8%]

648

0.685

1.11 [0.96; 1.29]

.155